ASPIRIN; BUTALBITAL; CAFFEINE; CODEINE PHOSPHATE | A075231 | LGM PHARMA SOLUTIONS LLC
| Petition | Type | Filed | Status | Petitioner |
|---|---|---|---|---|
Lachman Consultant Services, Inc. - Citizen Petition FDA-2008-P-0156 · 3 docket documents Lachman Consultant Services, Inc. filed this petition under Section 505(j)(2)(C) of the Federal Food, Drug, and Cosmetic Act requesting that the FDA declare Butalbital, Aspirin, Caffeine, and Codeine Phosphate Capsules USP (50 mg/500 mg/40 mg/30 mg) suitable for submission as an ANDA, with Fiorinal | Other | 2008-09-05 | Granted | — |
Source: Regulations.gov. FDA citizen petitions matched by application number.
Highest NADAC/Unit
$1.06
per ea
Lowest NADAC/Unit
$1.06
per ea
Brand NDCs
0
Generic NDCs
2
| NDC Description | NADAC/Unit | Unit | Type | Generic NADAC | Effective |
|---|---|---|---|---|---|
| 51991007401ASCOMP WITH CODEINE CAPSULE | $1.06 | EA | Generic | — | 2026-06-17 |
| 51991007405ASCOMP WITH CODEINE CAPSULE | $1.06 | EA | Generic | — | 2026-06-17 |
Source: NADAC (data.medicaid.gov). Prices reflect national average acquisition costs for retail community pharmacies.
No patent or exclusivity listings for this strength.